In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) vaccine (brand name mRESVIA) to protect patients aged 60 and over against ...

The CDC encourages doctors to vaccinate babies and adults over 60 years old, with two RSV vaccines for seniors, GSK’s Arexvy (88% effective) and Pfizer’s Abrysvo(85% effective), currently ...

Investigators randomly assigned participants in the United States and Japan in a 1:1 ratio to receive one dose of Pfizer’s bivalent (two-strain) RSV Prefusion F (RSVpreF) vaccine (Abrysvo ...

The syndrome has cropped up as a side effect in trials for RSV vaccines like Pfizer’s Abrysvo and GSK’s Arexvy. The single case of Guillain-Barré syndrome in the mRNA-1403 trial is ...